Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.

Authors:
Sebastiano Rizzardo
Sebastiano Rizzardo
Azienda Ospedaliera Universitaria Integrata di Verona
Verona | Italy
Massimiliano Lanzafame
Massimiliano Lanzafame
G.B. Rossi Hospital
Emanuela Lattuada
Emanuela Lattuada
G.B. Rossi Hospital
Stefano Nicole
Stefano Nicole
G.B. Rossi University Hospital
Leonardo Calza
Leonardo Calza
S. Orsola Hospital
Italy
Evelina Tacconelli
Evelina Tacconelli
Catholic University
Italy

Int J STD AIDS 2019 Apr 10;30(5):467-471. Epub 2019 Jan 10.

1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.

Raltegravir (RAL) is an HIV-1 integrase strand transfer inhibitor that is well established as a component of highly active antiretroviral therapy regimens for the treatment of adults living with human immunodeficiency virus (HIV), due to its high virological efficacy and good tolerability profile. To date, limited data are available on the use of RAL with abacavir/lamivudine (ABC/3TC). We investigated retrospectively 62 HIV-1 infected patients managed by three Italian Infectious Diseases Outpatient Departments, including 57 treatment-experienced patients and 5 treatment-naïve patients, treated with ABC/3TC plus RAL. In all five naïve patients (100%), virological suppression was achieved and maintained , while 55 experienced patients (96.5%) maintained viral suppression at the most recent review. In the treatment-experienced patients, we observed a significant decrease in triglyceride levels (p < 0.01), while liver transaminases, renal function and cholesterol levels remained substantially stable. In the 34 treatment-experienced patients who switched from a protease inhibitor (PI)-based regimen, we observed a significant improvement of total cholesterol (p=0.03) and triglyceride (p < 0.01) levels. No significant alterations were found on renal and liver function and serum lipid profile of treatment-naïve patients. Despite the small number of participants, results support the efficacy and safety of ABC/3TC plus RAL, either in treatment-naïve or treatment-experienced patients.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0956462418817049DOI Listing
April 2019
1 Read

Publication Analysis

Top Keywords

treatment-naïve patients
8
treatment-experienced patients
8
patients
7
hiv-1 infected
4
retrospectively hiv-1
4
investigated retrospectively
4
abacavir/lamivudine abc/3tc
4
abc/3tc investigated
4
infected patients
4
patients managed
4
infectious diseases
4
diseases outpatient
4
italian infectious
4
three italian
4
managed three
4
ral abacavir/lamivudine
4
data ral
4
virus hiv
4
hiv high
4
immunodeficiency virus
4

References

(Supplied by CrossRef)
Article in Jpn J Infect Dis
Suzuki A et al.
Jpn J Infect Dis 2016
Article in Jpn J Infect Dis
Kang SJ et al.
Jpn J Infect Dis 2013
Article in Infect Dis
Galli L et al.
Infect Dis 2017
Article in Scan J Infect Dis
Fabbiani M et al.
Scan J Infect Dis 2014
Article in PLoS One
Troya J et al.
PLoS One 2018
Article in AIDS Res Hum Retroviruses
Martinez E et al.
AIDS Res Hum Retroviruses 2013
Article in Lancet Infect Dis
Raffi F et al.
Lancet Infect Dis 2013
Article in HIV Clin Trials
Young B et al.
HIV Clin Trials 2015

Similar Publications